Vaccine holds out hope for allergy sufferers

Apr 27 (Agence de Presse Medicale for Reuters Health) - Switzerland's Cytos Biotech says follow-up results from a study of its vaccine for allergic diseases show significant long-term efficacy in people who are allergic to house dust mites -- a common cause of sneezing, wheezing, eye inflammation and asthma.

The intermediate-phase trial involving 20 patients, aged 18-56, with nose and eye symptoms and asthma caused by house dust mite allergy, evaluated the safety, tolerability and efficacy of a 10-week treatment with the vaccine, CYT005-AllQbG10, in conjunction with house dust mite allergen......Read the whole article HERE